# MONOCLONAL ANTIBODIES APPLIED TO TREAT/DIAGNOSE CANCER

> **NIH NIH R01** · ROSWELL PARK CANCER INSTITUTE · 1987 · $133,126

## Abstract

A panel of monoclonal antibodies (MABs) that bind preferentially to human
lung tumors has been developed that represents an important diagnostic and
therapeutic set of reagents.  These antibodies are unique in that they have
been derived from hybrids that were produced by fusing spleed cells of mice
immunized with surgically excised lung tumors (as opposed to tumor cell
lines) to a nonsecreting murine myeloma.  A characteristic reactivity
pattern for each MAb has been established by screening against a large
number of normal and neoplastic fresh tissues as well as cultured cell
lines.  We have established that one of the dominant antigenic determinants
recognized by our MAbs is a glycoprotein with a molecular weight of 158,000
(gp158).  The gp158 molecule has been detected on adenocarcinomas, alveolar
carcinomas and a portion of the large cell tumors of the lung.  The gp158
molecule is undetectable in all of the normal human tissues tested;
including lung, colon, brain, kidney, heart, stomach, erythrocytes and
lymphocytes.  These MAbs have been used to establish a simple rapid and
sensitive assay that will detect the presence of the gp158 molecule (or
other lung tumor associated antigens) on cells or alternatively, antibodies
directed against the lung tumor associated antigen(s).  We propose to use
our panel of MAbs with the former immunoassay to characterize non-small
cell lung tumors based upon their reactivity with the library of MAbs.  Our
ultimate goal will be to correlate the reactivity profile of a tumor with
the patient's prognosis and with the most effective therapeutic modality
for treatment of this tumor phenotype.  We also recognize that our set of
MAbs has a significant therapeutic potential.  In the course of our work on
this project we have been able to prepare cytotoxic drug-containing
liposomes (to which we have covalently coupled to the surface anti-idiotype
antibody) and to selectively deliver these liposomes in vitro and in vivo
to a tumor containing the idiotype on the cell surface.  We shall continue
to use this tumor model to resolve anticipated problems and to improve upon
the efficiency of our drug delivery system.  One method by which we may
improve upon efficiency is by incorporating the fusion-protein from Sendai
virus into the lipid bilayer of the antibody-modified drug-containing
liposomes.  What we learn from this model will be applied to develop
protocols of immunospecific targeting of drug-containing liposomes to human
lung tumors.

## Key facts

- **NIH application ID:** 3171323
- **Project number:** 5R01CA033462-06
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE
- **Principal Investigator:** RICHARD B BANKERT
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $133,126
- **Award type:** 5
- **Project period:** 1982-09-30 → 1988-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171323

## Citation

> US National Institutes of Health, RePORTER application 3171323, MONOCLONAL ANTIBODIES APPLIED TO TREAT/DIAGNOSE CANCER (5R01CA033462-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171323. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*